NCT00268385 2026-03-18
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
34 trialsNCT05413304 2026-02-27
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03535350 2025-09-30
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT00639262 2025-05-02
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
Thomas Jefferson University
Phase 1 Completed
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT03705351 2024-03-04
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
Phase 1 Terminated
NCT00387400 2023-08-04
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT01528046 2023-01-13
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04200066 2022-08-22
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
Phase 1 Withdrawn
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT00994071 2019-12-09
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01480050 2019-05-22
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00734526 2018-11-09
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00027625 2018-06-27
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00547131 2018-04-17
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
City of Hope Medical Center
Phase 1 Completed
NCT01390571 2018-02-05
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
Cancer Research UK
Phase 1 Completed
NCT00437957 2017-02-23
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT00516607 2015-02-10
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00005951 2014-08-22
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Phase 1 Completed
NCT00612989 2014-07-16
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Duke University
Phase 1 Completed
NCT00650923 2014-05-30
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00006024 2014-02-13
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
Children's Oncology Group
Phase 1 Completed
NCT00610571 2013-10-25
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Duke University
Phase 1 Completed
NCT00006474 2013-06-20
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Duke University
Phase 1 Completed
NCT00354068 2013-03-28
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
Phase 1 Completed
NCT00544284 2013-02-15
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Phase 1 Completed
NCT00614978 2012-09-19
LAPTEM
Jules Bordet Institute
Phase 1 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00025558 2011-03-28
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
NYU Langone Health
Phase 1 Completed
NCT00003567 2010-06-11
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated